AR079008A1 - Co-cristales de tramadol y coxibs, proceso de preparacion y composicion farmaceutica - Google Patents

Co-cristales de tramadol y coxibs, proceso de preparacion y composicion farmaceutica

Info

Publication number
AR079008A1
AR079008A1 ARP100103777A ARP100103777A AR079008A1 AR 079008 A1 AR079008 A1 AR 079008A1 AR P100103777 A ARP100103777 A AR P100103777A AR P100103777 A ARP100103777 A AR P100103777A AR 079008 A1 AR079008 A1 AR 079008A1
Authority
AR
Argentina
Prior art keywords
crystal
tramadol
increased
solution
coxib
Prior art date
Application number
ARP100103777A
Other languages
English (en)
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/007451 external-priority patent/WO2010043412A1/en
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR079008A1 publication Critical patent/AR079008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud se refiere a co-cristales de tramadol y formadores de co-cristal seleccionados de NSAIDs/coxibs, procesos para preparacion de los mismos y sus usos como medicamentos o en formulaciones farmacéuticas, más particularmente para el tratamiento del dolor. Reivindicacion 1: Un co-cristal que comprende tramadol tanto como una base libre o como una sal fisiologicamente aceptable y por lo menos un coxib. Reivindicacion 2: Un co-cristal de acuerdo con la reivindicacion 1, donde el coxib se elige de tal manera que si se compara tanto con tramadol solo, como una mezcla de tramadol y el correspondiente coxib, como agente/s activo/s: la solubilidad del co-cristal se incrementa; y/o la respuesta de dosis del co-cristal se incrementa; y/o la eficacia del co-cristal se incrementa; y/o la disolucion del co-cristal se incrementa; y/o la biodisponibilidad del co-cristal se incrementa; y/o la estabilidad del co-cristal se incrementa; y/o la higroscopicidad del co-cristal se disminuye; y/o la diversidad de forma del co-cristal se disminuye; y/o la morfología del co-cristal se modula. Reivindicacion 13: Un proceso para la produccion de un co-cristal de acuerdo con reivindicacion 1 que comprende los pasos de: (a) disolver o suspender el coxib en un solvente; opcionalmente calentando la solucion o dispersion a una temperatura por encima de temperatura ambiente y por debajo del punto de ebullicion de la solucion o dispersion; (b) disolver junto con, o después, o antes del paso (a) tramadol ya sea como una base libre o como una sal en un solvente, opcionalmente combinado con el paso (a) mediante disolucion de tramadol ya junto con el coxib en el paso (a), (c) opcionalmente anadir la solucion de (b) a una solucion de (a) y mezclarlos; (d) opcionalmente anadir un solvente a la solucion de (a), (b) o (c) y mezclarlos; (e) enfriar la solucion/dispersion mezclada del paso (a), (b), (c) o (d) a temperatura ambiente o por debajo; (f) opcionalmente evaporar parte o todo el solvente; y (g) recoger mediante filtracion los co-cristales resultantes. Reivindicacion 14: Una composicion farmacéutica caracterizada por cuanto comprende una cantidad terapéuticamente eficaz del co-cristal de acuerdo con cualquiera de las reivindicaciones 1 a 12 en un medio fisiologicamente aceptable.
ARP100103777A 2009-10-16 2010-10-15 Co-cristales de tramadol y coxibs, proceso de preparacion y composicion farmaceutica AR079008A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2009/007451 WO2010043412A1 (en) 2008-10-17 2009-10-16 Co-crystals of tramadol and nsaids
PCT/EP2010/002385 WO2011044962A1 (en) 2009-10-16 2010-04-19 Co-crystals of tramadol and coxibs

Publications (1)

Publication Number Publication Date
AR079008A1 true AR079008A1 (es) 2011-12-21

Family

ID=42272447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103777A AR079008A1 (es) 2009-10-16 2010-10-15 Co-cristales de tramadol y coxibs, proceso de preparacion y composicion farmaceutica

Country Status (20)

Country Link
US (1) US20230057884A1 (es)
JP (1) JP5399564B2 (es)
KR (1) KR101471585B1 (es)
CN (3) CN104817501B (es)
AR (1) AR079008A1 (es)
AU (1) AU2010306168B2 (es)
BR (1) BR112012005011B8 (es)
CA (1) CA2771665C (es)
CO (1) CO6511248A2 (es)
HK (1) HK1173380A1 (es)
HR (1) HRP20130316T1 (es)
IL (1) IL218256A (es)
MA (1) MA33742B1 (es)
MX (1) MX2012003050A (es)
NZ (1) NZ598353A (es)
PT (1) PT2488169E (es)
SG (1) SG178835A1 (es)
TW (1) TWI441630B (es)
WO (1) WO2011044962A1 (es)
ZA (1) ZA201201892B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
CN107648228A (zh) * 2017-10-24 2018-02-02 珠海赛隆药业股份有限公司 一种帕瑞昔布钠与盐酸曲马多组成的复合物及其用途
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
JP2022533580A (ja) * 2019-05-14 2022-07-25 エステベ ファーマシューティカルズ，ソシエダッド アノニマ トラマドールの濫用傾向を低減させながら疼痛を治療するためのトラマドールおよびセレコキシブからなる共結晶の使用
CN112007024A (zh) * 2019-05-28 2020-12-01 江苏恒瑞医药股份有限公司 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
WO2008085674A1 (en) * 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination

Also Published As

Publication number Publication date
SG178835A1 (en) 2012-05-30
KR20120099212A (ko) 2012-09-07
BR112012005011A2 (pt) 2016-05-03
AU2010306168B2 (en) 2014-10-30
CN104817501A (zh) 2015-08-05
CN104817501B (zh) 2017-09-22
KR101471585B1 (ko) 2014-12-10
CN104844513B (zh) 2018-08-07
BR112012005011B8 (pt) 2021-05-25
CA2771665C (en) 2015-10-06
IL218256A0 (en) 2012-04-30
IL218256A (en) 2017-05-29
ZA201201892B (en) 2012-11-28
HRP20130316T1 (en) 2013-05-31
JP2013507402A (ja) 2013-03-04
PT2488169E (pt) 2013-04-03
NZ598353A (en) 2014-01-31
CN104844513A (zh) 2015-08-19
CA2771665A1 (en) 2011-04-21
CO6511248A2 (es) 2012-08-31
MA33742B1 (fr) 2012-11-01
WO2011044962A1 (en) 2011-04-21
AU2010306168A1 (en) 2012-03-15
TW201116273A (en) 2011-05-16
MX2012003050A (es) 2012-05-29
TWI441630B (zh) 2014-06-21
US20230057884A1 (en) 2023-02-23
BR112012005011B1 (pt) 2021-01-19
CN102573825A (zh) 2012-07-11
HK1173380A1 (en) 2013-05-16
CN102573825B (zh) 2015-04-22
JP5399564B2 (ja) 2014-01-29

Similar Documents

Publication Publication Date Title
AR079008A1 (es) Co-cristales de tramadol y coxibs, proceso de preparacion y composicion farmaceutica
CA2751884C (en) Transdermal administration of tamsulosin
JP4542743B2 (ja) ピリドン誘導体の溶液状医薬組成物
AR052173A1 (es) Forma de dosificacion solida que comprende un inhibidor de bomba protonica y una suspension obtenida de la misma
JP2013514347A (ja) デクスイブプロフェン経皮ヒドロゲルの組成物
JP2012255026A5 (es)
JP2014098046A (ja) ジクロフェナクの新規な非水性外用溶液およびそれを調製するためのプロセス
EP1656095A2 (en) N,n-dihalogenated amino acids and derivatives
ES2643643T3 (es) Composición portadora para suministro de un compuesto biológicamente activo
BRPI0712325A2 (pt) processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal
AR081671A1 (es) Derivados de 6,7-dihidro-5h-benzo[7]anulenos, preparaciones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
JP2005535584A5 (es)
WO2011049058A1 (ja) ジクロフェナクナトリウム含有水性貼付剤
JP2014508814A (ja) リチウム組成物
AR090187A1 (es) Procedimiento de elaboracion de microcapsulas entericas de alginato por gelacion ionica que contienen diclofenac o una de sus sales y composicion farmaceutica multiparticulada que las contiene
ES2841992T3 (es) Formulación transdérmica que contiene inhibidores de COX
CN101313899A (zh) 一种含有溴芬酸钠的眼用药物组合物
SA521430973B1 (ar) صيغ علاجية ثابتة في مذيبات قطبية غير بروتونية وطرق لتصنيعها
BR112022017509A2 (pt) Composições terapêuticas de liberação prolongada estáveis em solventes polares apróticos e métodos de fabricação das mesmas
ES2732729T3 (es) Composiciones farmacéuticas acuosas tópicas orales de flurbiprofeno y dexpantenol
CN103505414A (zh) 丁苯酞滴鼻剂及其制备方法
US11850220B2 (en) Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
JPS5962518A (ja) 局所用外用剤およびその製造法
US20130261189A1 (en) Polyvinylpyrrolidone-containing acetaminophen liquid formulations
JP5994093B2 (ja) ロキソプロフェンナトリウム含有パップ剤

Legal Events

Date Code Title Description
FG Grant, registration